Post COVID-19 "Long Haulers"
COVID-19 Pandemic Heightens Need for Rapid Pulmonary Diagnostic Innovation
50% of COVID-19 deaths are co-infected with bacterial pneumonia

Ventilator Associated Pneumonia (VAP)
30% to 50% mortality rate of patients with VAP

The world's first breath test designed to detect & monitor pulmonary infections.

The only test that has the potential to differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.

Current standard of care vs Avisa BreathTest chart

Current standard of care chart
Avisa BreathTest chart

A Value-Based, Cost Advantaged Product would be a Win for Patient, Doctor, Hospital and Payer

Learn More About Clinical Applications

  AVISA BreathTest Culture PCR Procalcitonin,  Proteomics Panel
Specimen Exhaled Breath Sputum Sputum Blood
Detects live organisms Yes No No No
Measures whole lung Yes No No No
Monitors treatment Yes No No Yes
Turnaround time <10 min 24 hrs to 3 days 4 hrs to 24 hrs 2 hrs to 4 hrs
Sensitivity High Low Moderate Moderate
Specificity High Urease High High Low
Point of care, portable Yes No No No
Test complexity Low High High Moderate
Complementary to ABT --- Yes Yes No

Interested in learning more?

Contact us today to speak with an Avisa Expert!

Contact Us

Subscribe to receive our press releases

Stock Info:
CSE:   AVBT $0.00